FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2242050593> ?p ?o ?g. }

• W2242050593 endingPage "10736" @default.
• W2242050593 startingPage "10736" @default.
• W2242050593 abstract "10736 Background: Recently, the combination chemotherapy including docetaxel (75 mg/m 2 ), doxorubicin (adriamycin) (50 mg/m 2 ), andcyclophosphamide (500 mg/m 2 ) has been reported to be effective as an adjuvant treatment for the early breast cancer patients. Though a few studies have been published to show preventive effect of the routine use of G-CSF and oral antibiotics on the severe neutropenia. We prosepctively tried to compare the possible role of this prophylactic measure on the prevention of high-grade neutropenia in breast cancer patients having this regimen in Korea. Methods: We prospectively compared prophylactic user group (100 patients) with non-use group (100 patients). Stage II breast cancer patients were enrolled for this study. We used three-day prescription of G-CSF (150 ug/day) and oral ciprofloxacin (500 mg/day) five days after the completion of each cycle for the user-group. Results: The percentage of febrile neutropenia was strikingly decreased in the user group (p < .01). Number of patients showing grade II, III neutropenia didn’t show statistical difference between groups. Averge days required to recover from the neutropenia was 2.7days in two groups. The nadir of neutropenia was between 7–10 days after each cycle regardless of the prophylaxis. The duration of neutropenia seems to be dependent on the presence of the fever over 38’C after the chemotherapy. Once the fever developed, the neutropenia was becoming severer and more protracted. Conclusions: We think this combination chemotherapy effective to be used as an adjuvant treatment for the early breast cancer patients. But more care should be provided to prevent severe neutropenia after each cycle. Routine use of this prophylaxis failed to show significant differences in the rate of occurence of the severe neutropenia. But, we think that the prophylaxis seems to e effective to prevent febrile neutropenia. So, we suggest the routine prophylactic use of G-CSF and oral ciprofloxacin should be considered to be used in breast patients having docetaxel, adriamycin, and cyclophosphamide. No significant financial relationships to disclose." @default.
• W2242050593 created "2016-06-24" @default.
• W2242050593 creator A5017028026 @default.
• W2242050593 creator A5048465109 @default.
• W2242050593 creator A5050636008 @default.
• W2242050593 creator A5063703190 @default.
• W2242050593 date "2006-06-20" @default.
• W2242050593 modified "2023-09-25" @default.
• W2242050593 title "Is the prophylactic use of colony stimulating factor and oral ciprofloxacin effective to prevent neutropenia in patients having docetaxel, doxorubicin, and cyclophosphamide for breast cancer as an adjuvant chemotherapy in Korea?" @default.
• W2242050593 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.10736" @default.
• W2242050593 hasPublicationYear "2006" @default.
• W2242050593 type Work @default.
• W2242050593 sameAs 2242050593 @default.
• W2242050593 citedByCount "0" @default.
• W2242050593 crossrefType "journal-article" @default.
• W2242050593 hasAuthorship W2242050593A5017028026 @default.
• W2242050593 hasAuthorship W2242050593A5048465109 @default.
• W2242050593 hasAuthorship W2242050593A5050636008 @default.
• W2242050593 hasAuthorship W2242050593A5063703190 @default.
• W2242050593 hasConcept C121608353 @default.
• W2242050593 hasConcept C126322002 @default.
• W2242050593 hasConcept C141071460 @default.
• W2242050593 hasConcept C143998085 @default.
• W2242050593 hasConcept C2776694085 @default.
• W2242050593 hasConcept C2776755627 @default.
• W2242050593 hasConcept C2777063308 @default.
• W2242050593 hasConcept C2778850193 @default.
• W2242050593 hasConcept C2781190966 @default.
• W2242050593 hasConcept C2781413609 @default.
• W2242050593 hasConcept C530470458 @default.
• W2242050593 hasConcept C71924100 @default.
• W2242050593 hasConcept C90924648 @default.
• W2242050593 hasConceptScore W2242050593C121608353 @default.
• W2242050593 hasConceptScore W2242050593C126322002 @default.
• W2242050593 hasConceptScore W2242050593C141071460 @default.
• W2242050593 hasConceptScore W2242050593C143998085 @default.
• W2242050593 hasConceptScore W2242050593C2776694085 @default.
• W2242050593 hasConceptScore W2242050593C2776755627 @default.
• W2242050593 hasConceptScore W2242050593C2777063308 @default.
• W2242050593 hasConceptScore W2242050593C2778850193 @default.
• W2242050593 hasConceptScore W2242050593C2781190966 @default.
• W2242050593 hasConceptScore W2242050593C2781413609 @default.
• W2242050593 hasConceptScore W2242050593C530470458 @default.
• W2242050593 hasConceptScore W2242050593C71924100 @default.
• W2242050593 hasConceptScore W2242050593C90924648 @default.
• W2242050593 hasIssue "18_suppl" @default.
• W2242050593 hasLocation W22420505931 @default.
• W2242050593 hasOpenAccess W2242050593 @default.
• W2242050593 hasPrimaryLocation W22420505931 @default.
• W2242050593 hasRelatedWork W1858470829 @default.
• W2242050593 hasRelatedWork W1973241390 @default.
• W2242050593 hasRelatedWork W1975239262 @default.
• W2242050593 hasRelatedWork W2011089291 @default.
• W2242050593 hasRelatedWork W2388730008 @default.
• W2242050593 hasRelatedWork W2560682459 @default.
• W2242050593 hasRelatedWork W2907256583 @default.
• W2242050593 hasRelatedWork W2980453143 @default.
• W2242050593 hasRelatedWork W3000675521 @default.
• W2242050593 hasRelatedWork W3032029751 @default.
• W2242050593 hasVolume "24" @default.
• W2242050593 isParatext "false" @default.
• W2242050593 isRetracted "false" @default.
• W2242050593 magId "2242050593" @default.
• W2242050593 workType "article" @default.